CHENGDU, China, Sept. 23 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a biopharmaceutical company that specializes in modernized traditional Chinese medicine, branded generics and other pharmaceuticals, publishes the updated corporate presentation which was presented at 2010 Roth Hawaii Conference and Rodman & Renshaw 2010 Annual Global Investment Conference in September at the Company's website:
About Tianyin Pharmaceutical
Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading biopharmaceutical company that is engaged in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and branded generics, equipped with two state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. Tianyin currently manufactures and markets a comprehensive portfolio of 56 products, of which 23 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. Tianyin achieved 10 new drug approvals at SFDA in 2009 and has a pipeline of 10 products pending regulatory approval that target various indications with considerable market potential. Tianyin has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com.
Safe Harbor Statement
The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.For more information, please contact:James Jiayuan Tong M.D. Ph.D.Chief Financial Officer, Chief Business & Development OfficerDirectorTianyin Pharmaceutical Co., Inc.Web:
+86-28-8551-6696 (Chengdu, China)+1-949-350-6999 (U.S.)+86-134-3655-0011 (China)Address: 23rd Floor Unionsun Yangkuo PlazaNo 2 Block 3 South Renmin RoadChengdu, 610041China
|SOURCE Tianyin Pharmaceutical Co., Inc.|
Copyright©2010 PR Newswire.
All rights reserved